Diabetes Mellitus is "A metabolic disorder characterized by hyperglycaemia resulting from defects in insulin secretion or insulin action or both". "Pharmacoeconomic analysis compares two or more medication options or strategies in terms of their cost and outcome or benefit".The objective of the study is to assess cost effective analysis of oral hypoglycaemic agents on the therapy of patients suffering from Type 2 DM[diabetes mellitus].A prospective observational study was conducted for a period of 6 months in the general medicine OPD[outpatient department] of SSIMS & RC[shammanur shivashankarappa instituteof medical science and research center]. Out-patients who were diagnosed with type 2 diabetes mellitus and receiving treatment specifically with oral hypoglycaemic agents were included in the study. After obtaining the approval from institutional ethical committee, a structured data collection form was developed to collect demographic datas, complete prescription details and other informations required in the study. Among all oral hypoglycaemic agents the most effective drug/combination in the region was identified.A total of 100 case records were identified and assessed in which 59% were males and 41% were females. Maximum number of patients with type 2 DM were from age group of 50-59 years followed by the age group of 40-49 years and then from 60-69 years.Metformin showed a highest difference in the FBS[fasting blood sugar] value of 4.30 mg/dl, while in combinational therapy Metformin + Glimepiride showed a highest difference in the FBS value of 5.94 mg/dl.In single anti-diabetic therapy, Glibenclamide showed a highest cost difference with 1233.2%, in combinational therapy Metformin + Glimepiride showed a maximum cost difference of 194.18%.Analysis of prescription data found that the single most commonly prescribed drug was Metformin and the most common combination used was Metformin + Glimepiride. Metformin alone and Metformin + Glimepiride showed maximum efficacy in control of glucose level. Glibenclamide alone and Metformin + Glimepiride showed most cost effectiveness.
